Table of Content

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 Company Market Share Analysis : Methodology
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1 Market segmentation & scope
4.2 Market size and growth prospects
4.2.1 Market Driver Analysis
4.2.1.1 Rise in importance of immunization across the globe
4.2.1.2 High predominance of chronic diseases
4.2.1.3 Technology advancements in the types of vaccines
4.2.1.4 Other drivers
4.2.2 Market Restraint Analysis
4.2.2.1 Cost of immunization
4.2.2.2 Lack of healthcare infrastructure
4.3 Penetration & growth prospect mapping
4.4 Vaccines - SWOT Analysis, By Factor (political & legal, economic and technological)
4.5 Industry Analysis - Porter's
4.6 Vaccines company market share/competitive landscape, 2015
Chapter 5 Market Categorization 1: Vaccines Type Estimates & Trend Analysis
5.1 Vaccine Market: Vaccine type movement analysis
5.2 Live attenuated vaccines
5.2.1 Live attenuated Vaccine Market, 2013 - 2024 (USD Million)
5.3 Inactivated vaccines
5.3.1 Inactivated Vaccine Market, 2013 - 2024 (USD Million)
5.4 Subunit vaccines
5.4.1 Subunit Vaccine Market, 2013 - 2024 (USD Million)
5.5 Toxoid vaccines
5.5.1 Toxoid Vaccine Market, 2013 - 2024 (USD Million)
5.6 Conjugate vaccines
5.6.1 Conjugate Vaccine Market, 2013 - 2024 (USD Million)
5.7 DNA vaccines
5.7.1 DNA Vaccine Market, 2013 - 2024 (USD Million)
5.8 Others
5.8.1 Other Vaccine Market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Vaccine Application Estimates & Trend Analysis
6.1 Vaccine Market: Application movement analysis
6.2 Infectious Diseases
6.2.1 Infectious Diseases market, 2013 - 2024 (USD Million)
6.3 Cancer
6.3.1 Cancer market, 2013 - 2024 (USD Million)
6.4 Autism
6.4.1 Autism market, 2013 - 2024 (USD Million)
6.5 Allergy
6.5.1 Allergy market, 2013 - 2024 (USD Million)
6.6 Others
6.6.1 Other applications market, 2013 - 2024 (USD Million)
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Type & Application
7.1 Vaccine Market share by region, 2015 & 2024
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.5 Latin America
7.5.1 Brazil
7.6 MEA
7.6.1 South Africa
Chapter 8 Competitive Landscape
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Merck & Co. Inc
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 GlaxoSmithKline plc (GSK)
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 SANOFI S.A
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Pfizer Inc.
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 NOVARTIS AG
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Takeda Pharmaceuticals
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Astellas Pharma Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Emergent BioSolutions
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 AstraZeneca
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Mitsubishi Tanabe
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives

List of Tables


TABLE 1 North America Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 2 North America Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 3 U.S. Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 4 U.S. Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 5 Canada Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 6 Canada Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 7 Europe Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 8 Europe Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 9 Germany Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 10 Germany Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 11 UK Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 12 UK Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 13 Asia Pacific Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 14 Asia Pacific Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 15 China Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 16 China Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 17 Japan Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 18 Japan Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 19 Latin America Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 20 Latin America Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 21 Brazil Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 22 Brazil Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 23 MEA Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 24 MEA Vaccine Market, by application, 2013 - 2024 (USD Million)
TABLE 25 South Africa Vaccine Market, by type, 2013 - 2024 (USD Million)
TABLE 26 South Africa Vaccine Market, by application, 2013 - 2024 (USD Million)